|
Pulmonary pleomorphic carcinoma harboring epidermal growth factor receptor mutation: Response to afatinib
Abeer Hussien Anter1, Majid Al-Jahel2, Rasha Mohamed AbdelLatif3, Mohamed Fouad AbdELmohsen4, Ahmed Shata5
1 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Egypt; Department of Oncology, King Fahad Hospital, Madinah, Saudi Arabia
2 Department of Oncology, King Fahad Hospital, Madinah, Saudi Arabia
3 Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Egypt
4 Department of Oncology, King Fahad Hospital, Madinah, Saudi Arabia; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Suez Canal University, Egypt
5 Department of Clinical Pharmacology, Faculty of Medicine, Mansoura University, Egypt
Correspondence Address:
Dr. Abeer Hussien Anter
Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCRP.JCRP_16_18
|
|
Pulmonary pleomorphic carcinoma (PPC) of the lung is a rare type of non-small cell lung cancer, exhibiting aggressive behavior and resistance to chemotherapy. We report a case of a 56-year-old female, diagnosed with PPC of the lung at clinical Stage IV in July 2017. She underwent first-line chemotherapy. The disease progressed after 6 cycles of chemotherapy, and we shift to afatinib due to presence of epidermal growth factor receptor (EGFR) mutation in exon 19. We then started second-line treatment in the form of molecular targeted therapy (afatinib), to which she had a partial response. Hence, we recommend the evaluation of driver gene alterations such as EGFR in the treatment of advanced PPC.
|
Next article
